Frontiers in Oncology: Quarterly Highlights. Quarter 1 2019 PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Frontiers in Oncology: Quarterly Highlights. Quarter 1 2019 PDF full book. Access full book title Frontiers in Oncology: Quarterly Highlights. Quarter 1 2019 by Giuseppe Giaccone. Download full books in PDF and EPUB format.
Author: Giuseppe Giaccone Publisher: Frontiers Media SA ISBN: 288945939X Category : Languages : en Pages : 213
Book Description
Foreword from the Field Chief Editor, Giuseppe Giaccone Once again Frontiers in Oncology has started the year on a positive note, breaking previous records for submissions and publications, as well as the number of Research Topic article collections posted. The journal continues to grow in size, adding an 18th section focusing on Cancer Metabolism, led by Michael Lisanti and Ubaldo Martinez-Outschoorn, and has brought on a total of five new Chief Editors. Here, introducing Frontiers in Oncology: Quarterly Highlights, we feature a collection of carefully selected articles published during the first quarter of 2019 across the different sections. With a record number of papers to choose from, the papers enclosed in this Special Edition highlight some of the recent advances across the different disciplines. With an array of papers looking at everything from translational research to association studies and clinical trial results, Frontiers in Oncology continues to publish high-quality research from researchers around the world. Many of the recently posted Research Topics in the journal focus on early diagnosis and prevention, as well as the importance of survivorship studies and outcomes of cancer treatment. Consideration of such aspects of cancer research and treatment is pivotal in the global effort towards increased survival rates and improved quality of life. With ASCO 2019 marking the end of Q1 and the transition into Q2, the journal looks forward to the rest of the year, and continuing to play an active role in the research community. Giuseppe Giaccone
Author: Giuseppe Giaccone Publisher: Frontiers Media SA ISBN: 288945939X Category : Languages : en Pages : 213
Book Description
Foreword from the Field Chief Editor, Giuseppe Giaccone Once again Frontiers in Oncology has started the year on a positive note, breaking previous records for submissions and publications, as well as the number of Research Topic article collections posted. The journal continues to grow in size, adding an 18th section focusing on Cancer Metabolism, led by Michael Lisanti and Ubaldo Martinez-Outschoorn, and has brought on a total of five new Chief Editors. Here, introducing Frontiers in Oncology: Quarterly Highlights, we feature a collection of carefully selected articles published during the first quarter of 2019 across the different sections. With a record number of papers to choose from, the papers enclosed in this Special Edition highlight some of the recent advances across the different disciplines. With an array of papers looking at everything from translational research to association studies and clinical trial results, Frontiers in Oncology continues to publish high-quality research from researchers around the world. Many of the recently posted Research Topics in the journal focus on early diagnosis and prevention, as well as the importance of survivorship studies and outcomes of cancer treatment. Consideration of such aspects of cancer research and treatment is pivotal in the global effort towards increased survival rates and improved quality of life. With ASCO 2019 marking the end of Q1 and the transition into Q2, the journal looks forward to the rest of the year, and continuing to play an active role in the research community. Giuseppe Giaccone
Author: Carlo C. Maley Publisher: Springer ISBN: 1493964607 Category : Medical Languages : en Pages : 266
Book Description
This is the ideal book for anyone contemplating starting a career in, or shifting their career to, studying the dynamics that drive cancer progression and its response to therapy. Topics include the theory and population genetics of cancers, genetic diversity within tumors (intra-tumor heterogeneity), understanding how mutant clones expand in tissues, the role of cancer stem cells in the dynamics of tumors, the evolution of metastasis, and how to improve cancer therapy by addressing the evolution of cancers in response to our interventions. There are also chapters on the patterns of cancer susceptibility in humans due to a mismatch between our modern environment and the environment in which our ancestors evolved, as well as a chapter on the evolution of cancer suppression mechanisms that have evolved in different species, particularly the large long-lived animals like elephants and whales that are better at suppressing cancers than humans. This book serves as a primer on the evolutionary and ecological theory of cancer- the framework upon which all the details of cancer may be hung. It is ideal for oncologists and cancer researchers interested in evolutionary theory, and evolutionary biologists and ecologists interested in gaining insights into cancer development and prevention.
Author: Petranel Theresa Ferrao Publisher: Frontiers Media SA ISBN: 2889196623 Category : Cancer Languages : en Pages : 79
Book Description
The process of Epithelial-Mesenchymal-Transition (EMT) is known to result in a phenotype change in cells from a proliferative state to a more invasive state. EMT has been reported to drive the metastatic spread of various cancers and has also been associated with drug resistance to cytotoxics and targeted therapeutics. Recently phenotype switching akin to EMT has been reported in non-epithelial cancers such as metastatic melanoma. This process involves changes in EMT-Transcription Factors (EMT-TFs), suggesting that phenotype-switching may be common to several tumour types. It remains unclear as to whether the presence of both Epilthelial-like and Mesenchymal-like cells are a pre-requisite for phenotype switching within a tumour, how this heterogeneity is regulated, and if alteration of cell phenotype is sufficient to mediate migratory changes, or whether drivers of cell migration result in an associated phenotype switch in cancer cells. Similarly it has yet to be clarified if cells in an altered phenotype can be refractory to drug therapy or whether mediators of drug resistance induce a concurrent phenotypic change. Little is known today about the underlying genetic, epigenetic and transient changes that accompany this phenotypic switch and about the role for the tumor micro-environment in influencing it. Hence this is currently an area of speculation and keen interest in the Oncology field with wide-ranging translational implications. In this Frontiers Research Topic, we discuss our current understanding of these concepts in various cancer types including breast cancer, colorectal cancer and metastatic melanoma. This topic covers how these processes of cellular and phenotypic plasticity are regulated and how they relate to cancer initiation, progression, dormancy, metastases and response to cytotoxics or targeted therapies.
Author: Paul Marks Publisher: PublicAffairs ISBN: 1610392531 Category : Medical Languages : en Pages : 274
Book Description
In 1950, a diagnosis of cancer was all but a death sentence. Mortality rates only got worse, and as late as 1986, an article in the New England Journal of Medicine lamented: "We are losing the war against cancer." Cancer is one of humankind's oldest and most persistent enemies; it has been called the existential disease. But we are now entering a new, and more positive, phase in this long campaign. While cancer has not been cured -- and a cure may elude us for a long time yet -- there has been a revolution in our understanding of its nature. Years of brilliant science have revealed how this individualistic disease seizes control of the foundations of life -- our genes -- and produces guerrilla cells that can attack and elude treatments. Armed with those insights, scientists have been developing more effective weapons and producing better outcomes for patients. Paul A. Marks, MD, has been a leader in these efforts to finally control this devastating disease. Marks helped establish the strategy for the "war on cancer" in 1971 as a researcher and member of President Nixon's cancer panel. As the president and chief executive officer for nineteen years at the world's pre-eminent cancer hospital, the Memorial Sloan-Kettering Cancer Center, he was instrumental in ending the years of futility. He also developed better therapies that promise a new era of cancer containment. Some cancers, like childhood leukemia and non-Hodgkin's lymphoma, that were once deadly conditions, are now survivable -- even curable. New steps in prevention and early diagnosis are giving patients even more hope. On the Cancer Frontier is Marks' account of the transformation in our understanding of cancer and why there is growing optimism in our ability to stop it.
Author: Tamara Ownsworth Publisher: Frontiers Media SA ISBN: 2889197824 Category : Medicine (General) Languages : en Pages : 144
Book Description
Neuro-oncology is a rapidly growing field concerned with scientific developments and clinical applications related to neuroscience, neuropsychology, cancer and oncology. Neuro-oncological disorders include cancers that directly affect the central nervous system (CNS), such as brain tumours and brain metastases, and non-CNS cancers with treatments that produce neurocognitive impairment. To date, the biological mechanisms and neuropsychological effects of brain tumour and cancer have been the dominant focus in neuro-oncology literature. In terms of psychosocial aspects of care, people’s understanding of their diagnosis and symptoms and how they cope with their illness has a major influence on their emotional well-being and quality of life.The development and evaluation of psychological and supportive care interventions for people with brain tumour is an area of emerging research and of high interest to health professionals working in the field. This Research Topic aims to enhance understanding of the psychological and social consequences of brain tumour and other cancers impacting neurocognitive function. It also aims to showcase new developments in assessment and psychosocial intervention approaches.
Author: International Agency for Research on Cancer Publisher: International Agency for Research on Cancer ISBN: 9789283230236 Category : Medical Languages : en Pages : 0
Book Description
A Working Group of 23 independent experts from 15 countries, convened by the International Agency for Research on Cancer (IARC) in November 2017, reviewed the scientific evidence and assessed the cancer-preventive and adverse effects of various methods of screening for colorectal cancer. Colorectal cancer is the third most common cancer in men and the second most common in women worldwide, and represents more than 10% of the global cancer burden. This publication provides evidence-based evaluations of the effectiveness of colorectal cancer screening in reducing colorectal cancer incidence and mortality. The Working Group also reviewed the body of evidence on the comparison of endoscopic and stool-based techniques, on the determinants of participation in screening programs, and on the most mature emerging techniques that may be alternatives to current practices for colorectal cancer screening, as well as presenting the different categories of high-risk populations and the surveillance strategies for such individuals.
Author: Lizza E.L Hendriks Publisher: Frontiers Media SA ISBN: 2889457079 Category : Languages : en Pages : 94
Book Description
Approximately 40% of lung cancer patients will develop central nervous system (CNS) metastases during the course of their disease. Most of these are brain metastases, but up to 10% will develop leptomeningeal metastases. Known risk factors for CNS metastases development are small cell lung cancer (SCLC), adenocarcinoma histology, epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK) rearranged lung cancer, advanced nodal status, tumor stage and younger age. CNS metastases can have a negative impact on quality of life (QoL) and overall survival (OS). The proportion of lung cancer patients diagnosed with CNS metastases has increased over the years due to increased use of brain imaging as part of initial cancer staging, advances in imaging techniques and better systemic disease control. Post contrast gadolinium enhanced magnetic resonance imaging (gd-MRI) is preferred, however when this is contra-indicated a contrast enhanced computed tomography (CE-CT) is mentioned as an alternative option. When CNS metastases are diagnosed, local treatment options consist of radiotherapy (stereotactic or whole brain) and surgery. Local treatment can be complicated by symptomatic radiation necrosis for which no high level evidence based treatment exists. Moreover, differential diagnosis with metastasis progression is difficult. Systemic treatment options have expanded over the last years. Until recently, chemotherapy was the only treatment option with a poor penetration in the CNS. Angiogenesis inhibitors are promising in the treatment of primary CNS tumors as well as radiation necrosis but clinical trials of anti-angiogenic agents in NSCLC have largely excluded patients with CNS metastases. Furthermore, research has also focused on methods to prevent development of CNS disease, for example with prophylactic cranial irradiation. Recently, checkpoint inhibitors have become available for NSCLC patients, and tyrosine kinase inhibitors (TKIs) have improved prognosis significantly in those with a druggable driver mutation. Newer TKIs are often designed to have better CNS penetration compared to first-generation TKIs. Despite advances in treatment options CNS metastases remain a problem in lung cancer and cause morbidity and mortality. This Research Topic provides an extensive resource of articles describing advances in CNS metastases management in lung cancer patients, from prevention to diagnosis and treatment.
Author: Jun-ichi Abe Publisher: ISBN: Category : Languages : en Pages : 0
Book Description
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.
Author: Qingxin Mu Publisher: Frontiers Media SA ISBN: 2889458105 Category : Languages : en Pages : 162
Book Description
Since the invention of nanomedicine decades ago, considerable progresses have been made, especially with cancer as a target. Nanoparticles have been proven to be powerful imaging tools or potent agents for cancer diagnosis, treatment and prevention. Active research spread from fundamental research to clinical investigations. This topic intends to cover several important aspects in this field including nanocarrier development, gene delivery, intrinsically active nanoparticles, tumor microenvironment, immunology, and toxicity.
Author: Giuseppe Giaccone
Author: Giuseppe Giaccone
Author: Carlo C. Maley
Author: Petranel Theresa Ferrao
Author: Lorenzo Manti
Author: Paul Marks
Author: Tamara Ownsworth
Author: International Agency for Research on Cancer
Author: Lizza E.L Hendriks
Author: Jun-ichi Abe
Author: Qingxin Mu